Pulkit Gupta

Pulkit Gupta, PhD, currently serves as a Board Observer at Orbis Medicines and Crossbow Therapeutics, Inc., and holds a similar position at HiberCell and Mariana Oncology. As Executive Director at Lilly Ventures and previously as Senior Director of Venture Science and Business Development at Eli Lilly and Company, Pulkit Gupta has extensive experience in the pharmaceutical sector. Prior roles include Director of Business Development Search & Evaluation at BeiGene and various positions at Merck, where contributions included leading therapeutic antibody discovery programs and playing a key role in the development of Zinplava, the first FDA-approved monoclonal antibody for preventing C. difficile recurrence. Pulkit Gupta has also held academic positions, including Adjunct Assistant Professor at the University of Illinois at Chicago and a postdoctoral fellowship at the same institution, focusing on key biological mechanisms. Pulkit Gupta earned a Ph.D. in Pharmaceutical Biotechnology from the University of Illinois Chicago and a B.Tech in Biotechnology from Kurukshetra University.